Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSphere®) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT)

NCT01887717 is registered in ClinicalTrials.gov with Boston Scientific Corporation as lead sponsor.

NCT NCT01887717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01887717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSphere®) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT)
Lead sponsor
Boston Scientific Corporation
Phase
Phase 3
Overall status
Terminated
Start date
February 27, 2014
Completion date
May 23, 2017
Enrollment
36 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma